Skip to main content

Biotest Value Stock - Dividend - Research Selection

Biotest AG Vz

ISIN: DE0005227235, WKN: 522723

Market price date: 27.05.2021
Market price: 29,10 EUR




Biotest AG Vz Fundamental data and company key figures of the share

Annual reports in EUR
Key figures 05-04-2021
Cash flow
Net operating cash flow -16.700.000
Capital Expenditures -27.000.000
Free cash flow -43.700.000
Balance sheet
Total Equity 441.600.000
Liabilities & Shareholders equity 1.131.300.000
Income statement
Net income -31.400.000
Eps (diluted) -0,810
Diluted shares outstanding 39.571.500
Net sales/revenue 484.200.000

Fundamental ratios calculated on: 27-05-2021

Ratios
Key figures 27-05-2021
Cash flow
P/C -69,43
   
P/FC -26,35
Balance sheet
ROI-2,78
ROE39,04
Income statement
P/E-35,93
Div. Yield0,14%
P/B2,63
P/S2,38


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolBIO3.DE
Market Capitalization1.406.240.128,00 USD
Country
IndicesCDAX,Prime All Share
Sectors
Raw Data SourceIFRS in Millionen EUR
Stock Split2015-07-15,3.0000/1.0000; 2013-06-12,477.000000/476.000000; 2005-10-13,641.000000/619.000000; 1997-06-13,735.000000/694.000000; 1996-09-02,10.000000/1.000000; 1994-09-01,845.000000/816.000000
Internetwww.biotest.de


Description of the company

Biotest AG is a Germany-based international supplier of biological medications. It diversifies its activities into three business segments: Therapy segment, Plasma and Services segment, as well as Other segment. Its Therapy segment comprises the development and production of blood plasma-based immunoglobulin clotting factors and albumins, which are used in diseases of the immune system, hematological diseases, and intensive care medicine. It also includes the preclinical and clinical development of monoclonal antibodies, indications for which include rheumatoid arthritis and blood cancer. Furthermore, the Companys Plasma and Services segment includes the areas of plasma sales and toll manufacturing. Its Other segment, includes retail business and costs that cannot be allocated to the Therapy segment or the Plasma and Services segment.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.biotest.de